Healthcare Industry News: HemoSense
News Release - October 30, 2008
Timothy I. Still Appointed CEO at AccumetricsSAN DIEGO, Oct. 30 -- (Healthcare Sales & Marketing Network) -- Accumetrics, Inc. has appointed Timothy I. Still to the additional position of Chief Executive Officer. Mr. Still has been serving in the capacity of President and Chief Operating Officer for the company since earlier this year.
"Tim has the right combination of industry, management, and startup experience for our Board," says Tony Arnerich, General Partner of Arnerich & Massena and Executive Chairman of the Board at Accumetrics. "His commercialization expertise and diagnostic market experience will be invaluable as we build key partnerships and move forward with the commercialization of our technology."
Mr. Still's background includes over 18 years of sales, marketing and business development experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused sales and marketing strategies within both large and small companies.
Prior to Accumetrics, Mr. Still was Executive Vice President and Chief Commercial Officer for HemoSense, a medical diagnostic company located in San Jose, California. He was instrumental in building HemoSense into a rapidly growing, publicly traded company which was acquired by Inverness Medical in November 2007.
Before joining HemoSense, Mr. Still served as Vice President of Sales and Marketing for Cholestech Corporation, and served in a variety of sales, marketing and business development roles for Boehringer Mannheim Corporation (now Roche Diagnostics).
Mr. Still received a B.S. degree (with Honors) in Biological Sciences from the University of California at Davis, and an MBA (Deans Scholar) in Marketing and Entrepreneurship from the University of Southern California.
About Accumetrics (http://www.accumetrics.com):
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
VerifyNow is the first simple and rapid system for measuring the individual response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix®, ReoPro®, and Integrilin®, the VerifyNow system provides a valuable tool to help physicians make informed treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.